Pfizer widens access to its anti-Covid pill — Analysis

Pfizer agreed to give a royalty-free licence to distribute its anti-coronavirus pills in almost 100 countries.

Pfizer won’t receive royalty income from the sale of the antiviral drug in 95 countries. This agreement was made with the Medicines Patent Pool, a UN-backed health organisation. MPP can grant sub-licenses. “qualified” Each country has its own generic drug manufacturers.

The countries covered by the deal comprise around 53% of the world’s population, Pfizer said. “We believe oral antiviral treatments can play a vital role in reducing the severity of Covid-19 infections, decreasing the strain on our healthcare systems and saving lives,” Pfizer CEO Albert Bourla said. 

We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs.

The drug PF07321332, which is trademarked under the name Paxlovid was tested in a phase two/three study. It reduced hospitalization and death rates by 89% for patients with Covid-19 who received it within 3 days of symptom onset. This drug can be used in conjunction with low-dose ritonavir (a medication that is used to treat HIV/AIDS). 

UN and WHO (World Health Organization) long urged companies to provide affordable vaccines for the developing world.

You think your friends might be interested in this story? This story is your chance to share it!



Related Articles

Back to top button